Enlivex Therapeutics Ltd.
ENLV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$15,014 | -$29,068 | -$31,060 | -$14,468 |
| Dep. & Amort. | $545 | $835 | $777 | $546 |
| Deferred Tax | $0 | $0 | $0 | -$5,590 |
| Stock-Based Comp. | $0 | $1,951 | $2,712 | $2,914 |
| Change in WC | -$1,218 | -$1,818 | $804 | -$1,357 |
| Other Non-Cash | $2,679 | $4,577 | $2,814 | $413 |
| Operating Cash Flow | -$13,008 | -$23,523 | -$23,953 | -$17,542 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$103 | -$236 | -$8,122 | -$1,625 |
| Net Acquisitions | $0 | $0 | -$9,705 | -$20,030 |
| Inv. Purchases | -$32,370 | -$26,166 | -$1,608 | -$104,417 |
| Inv. Sales/Matur. | $39,239 | $301 | $72,254 | $67,634 |
| Other Inv. Act. | $2,293 | $133 | $9,705 | $20,030 |
| Investing Cash Flow | $9,059 | -$25,968 | $62,524 | -$38,408 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $6,454 | $360 | $150 | $53,174 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $2 | $0 | $150 | $7,808 |
| Financing Cash Flow | $6,454 | $360 | $150 | $60,982 |
| Forex Effect | $0 | $0 | $0 | -$408 |
| Net Chg. in Cash | $2,505 | -$49,131 | $38,721 | $4,624 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $1,226 | $50,357 | $11,636 | $7,012 |
| End Cash | $3,731 | $1,226 | $50,357 | $11,636 |
| Free Cash Flow | -$13,111 | -$23,759 | -$32,075 | -$19,167 |